Stocks · News reference
Akebia Therapeutics Announces Positive Data from VOICE Trial of Vafseo
Akebia Therapeutics reported positive results from the Vafseo Outcomes In-Center Experience (VOICE) trial, demonstrating improved safety outcomes for dialysis patients treated with vadadustat.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Akebia Therapeutics, Inc. (AKBA)
Filed: 2026-10-23 AccNo: 0001517022-26-000075 Size: 149 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
BTIG Reiterates Buy on Akebia Therapeutics, Maintains $4 Price Target
BTIG analyst Julian Harrison reiterates Akebia Therapeutics (NASDAQ:AKBA) with a Buy and maintains $4 price target.